Scripta Therapeutics

Scripta Therapeutics develops therapeutics that modulate transcription factor activity to restore health, flipping the traditional drug discovery paradigm by targeting the underlying biological causes of disease rather than downstream consequences. The company focuses on understanding and manipulating master controllers of biology, searching for drugs with the potential not just to delay disease progression but to halt or even reverse it. Scripta's approach is built on best-in-class AI/ML models and follows a three-stage process: genome-wide mapping of transcription factors that define and drive disease, identification and prediction of molecules and targets that modulate those transcription factors, and validation of results in pre-mapped, patient-derived models. This unbiased approach can be applied to any disease, revealing novel therapeutics with transformative potential. The company's initial focus is on finding therapies that truly change the course of neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Scripta combines pharma, biotech, and disease biology expertise with computational power, led by CEO and Founder Peter Hamley, VP of Machine Learning Jerry Huang, VP of Bioinformatics Andy Walker, VP of Biology John Blackwood, and academic co-founder Professor Noel Buckley. The company has implemented an ESG strategy from day one as a core operational principle, and publishes thought leadership on AI's role in drug discovery. Founded in 2025 and headquartered in Oxford, United Kingdom, Scripta Therapeutics has raised $11.9M in seed funding from investors including Oxford Science Enterprises, Apollo Health Ventures, AlbionVC, YZR Capital, Parkwalk, Oxford University Innovation, and Albion Capital Group.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based,

Neurology > Drugs > Neurodegenerative > Diversified

College Wise > University of Cambridge, Imperial College London